Stock EPRX EUPRAXIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Market Closed - Toronto S.E.
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
3.65 CAD -4.20% Intraday chart for Eupraxia Pharmaceuticals Inc. -6.41% -32.03%
May. 23 Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis MT
May. 23 Eupraxia Pharmaceuticals Inc. Brief: Announcing Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
MT
Eupraxia Pharmaceuticals Inc. Brief: Announcing Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
MT
Sector Update: Health Care Stocks Lower Premarket Wednesday
MT
Sector Update: Health Care
MT
Eupraxia Pharmaceuticals Announces Data from the Phase 1b/2a RESOLVE Clinical Trial
CI
Eupraxia Pharmaceuticals Reports Positive Data From Eosinophilic Esophagitis Treatment Study -- Shares Rise After Hours
MT
Update On Eupraxia Pharmaceuticals: Now Up 40% In US After Hours, Was Up As Much As 70%
MT
Eupraxia Pharmaceuticals Up 70% In US After Hours As Announces New "Positive" Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
MT
Eupraxia Pharmaceuticals Inc. Brief: Announcing New "Positive" Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
MT
Eupraxia Pharmaceuticals Inc. Announces New Positive Data from Resolve Phase 1B/2A Trial of Ep-104Gi for Treatment of Eosinophilic Esophagitis
CI
Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
MT
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Eupraxia Pharmaceuticals Forms Gastrointestinal Clinical Advisory Board
MT
Top Premarket Decliners
MT
Eupraxia Pharmaceuticals Inc. Brief: Begins Trading on Nasdaq Today
MT
Eupraxia Pharmaceuticals Inc. Brief: Says to Begin Trading on Nasdaq on April 5, 2024
MT
Eupraxia Pharmaceuticals Inc. Brief: Says incurred a net loss of US$10.6 million for Q4, versus $7.8 million for the three months ended December 31, 2022
MT
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Toronto Stocks Edge Forward; Shares of Altius Minerals Rise on 4Q Revenue Beat
DJ
Update on Eupraxia Pharmaceuticals Announcing Updated "Positive" Clinical Data in EP-104GI RESOLVE Trial for Treatment of Eosinophilic Esophagitis
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EPRX Stock
  4. News Eupraxia Pharmaceuticals Inc.
  5. Highlights